©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Pharmacol Ther. Nov 6, 2015; 6(4): 145-155
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.145
Published online Nov 6, 2015. doi: 10.4292/wjgpt.v6.i4.145
Pharmacotherapy for the management of achalasia: Current status, challenges and future directions
Ammar Nassri, Department of Internal Medicine, University of Texas at Austin Dell Medical School, Austin, TX 78701, United States
Zeeshan Ramzan, Gastrointestinal Section, Department of Internal Medicine, VA North Texas Healthcare System, Dallas, TX 75216, United States
Zeeshan Ramzan, Department of Medicine, Division of Gastroenterology and Hepatology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390, United States
Author contributions: Nassri A and Ramzan Z contributed equally to this work.
Conflict-of-interest statement: The authors have no conflicts of interest.
Correspondence to: Zeeshan Ramzan, MD, Assistant Professor, Gastrointestinal Section, Department of Internal Medicine, VA North Texas Healthcare System, 4500 S. Lancaster Road, Dallas, TX 75216, United States. zeeshanramzan@hotmail.com
Telephone: +1-214-8571591
Received: June 24, 2015
Peer-review started: June 26, 2015
First decision: August 26, 2015
Revised: September 6, 2015
Accepted: October 16, 2015
Article in press: October 19, 2015
Published online: November 6, 2015
Processing time: 141 Days and 11.6 Hours
Peer-review started: June 26, 2015
First decision: August 26, 2015
Revised: September 6, 2015
Accepted: October 16, 2015
Article in press: October 19, 2015
Published online: November 6, 2015
Processing time: 141 Days and 11.6 Hours
Core Tip
Core tip: Botulinum toxin (BT) injection is the most common and effective pharmacological therapy used in the treatment of achalasia, and is commonly used in the elderly, those with multiple comorbidities, patients at high risk for surgery and as a salvage therapy. This article discusses new advances related to the pharmacological management of achalasia that may help to optimize minimally invasive treatment approaches in patients with achalasia, and discusses improvements in endoscopic injection techniques, the use of sclerosants, new BT formulations, alternate serotypes, sprouting inhibitors and designer recombinant BT formulations.